发布求助
文献互助 智能选刊 最新文献

Aktuelle Urologie最新文献

筛选
英文 中文
Skrotumeingriffe: Schmerzkontrolle mit Gabapentin. 用加巴喷丁控制疼痛。
IF 0.3 4区 医学
Aktuelle Urologie Pub Date : 2024-12-01 Epub Date: 2024-12-03 DOI: 10.1055/a-2321-2061
{"title":"Skrotumeingriffe: Schmerzkontrolle mit Gabapentin.","authors":"","doi":"10.1055/a-2321-2061","DOIUrl":"https://doi.org/10.1055/a-2321-2061","url":null,"abstract":"","PeriodicalId":7513,"journal":{"name":"Aktuelle Urologie","volume":"55 6","pages":"490"},"PeriodicalIF":0.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Histopathological analysis of germ cell tumours: aspects to consider]. [生殖细胞肿瘤的组织病理学分析：需要考虑的方面]。
IF 0.3 4区 医学
Aktuelle Urologie Pub Date : 2024-12-01 Epub Date: 2024-09-05 DOI: 10.1055/a-2363-4744
Alexander Fichtner, Daniel Nettersheim, Felix Bremmer
{"title":"[Histopathological analysis of germ cell tumours: aspects to consider].","authors":"Alexander Fichtner, Daniel Nettersheim, Felix Bremmer","doi":"10.1055/a-2363-4744","DOIUrl":"10.1055/a-2363-4744","url":null,"abstract":"<p><p>Germ cell tumours (GCT) are the most common testicular tumours and form a heterogenous group of tumours with different biological behaviour. Based on differences regarding patient age at first manifestation, morphological characteristics and molecular changes, they are divided into three different groups of GCTs (type I-III). For treatment and prognosis, an exact histopathological analysis of an orchiectomy resection specimen is very important, including the specification of all different histological subtypes with their proportional distribution. This article describes the approach of the preparation of a resection specimen and the histopathological analysis of a testicular tumour. In addition, it describes cases in which additional tools like immunohistochemical and molecular analyses are necessary. Furthermore, the current WHO classification of testicular GCT is discussed.</p>","PeriodicalId":7513,"journal":{"name":"Aktuelle Urologie","volume":" ","pages":"528-536"},"PeriodicalIF":0.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142138995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urothelkarzinom: Urintest CxbT verringert Zystoskopien bei Mikrohämaturien. CxbT可降低膀胱癌的发病率。
IF 0.3 4区 医学
Aktuelle Urologie Pub Date : 2024-12-01 Epub Date: 2024-12-03 DOI: 10.1055/a-2321-2078
{"title":"Urothelkarzinom: Urintest CxbT verringert Zystoskopien bei Mikrohämaturien.","authors":"","doi":"10.1055/a-2321-2078","DOIUrl":"https://doi.org/10.1055/a-2321-2078","url":null,"abstract":"","PeriodicalId":7513,"journal":{"name":"Aktuelle Urologie","volume":"55 6","pages":"496-498"},"PeriodicalIF":0.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ProstataCa – Extraprostatische Ausdehnung als Risikofaktor erst ab ISUP Grad 2. 前列腺癌-前列腺外扩张作为ISUP 2级以上的危险因素。
IF 0.3 4区 医学
Aktuelle Urologie Pub Date : 2024-12-01 Epub Date: 2024-12-03 DOI: 10.1055/a-2321-2423
{"title":"ProstataCa – Extraprostatische Ausdehnung als Risikofaktor erst ab ISUP Grad 2.","authors":"","doi":"10.1055/a-2321-2423","DOIUrl":"https://doi.org/10.1055/a-2321-2423","url":null,"abstract":"","PeriodicalId":7513,"journal":{"name":"Aktuelle Urologie","volume":"55 6","pages":"500"},"PeriodicalIF":0.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
S2k-Leitlinie „Harninkontinenz bei geriatrischen Patienten“ – Teil 3: Operative Therapie der Harninkontinenz. S2K指南“老年患者尿失禁-第3部分：尿失禁的手术治疗”。
IF 0.3 4区 医学
Aktuelle Urologie Pub Date : 2024-12-01 Epub Date: 2024-12-03 DOI: 10.1055/a-2288-2572
Andreas Wiedemann, Barbara Bojack, Claudia Drews, Ruth Kirschner-Hermanns, Klaus Becher
{"title":"S2k-Leitlinie „Harninkontinenz bei geriatrischen Patienten“ – Teil 3: Operative Therapie der Harninkontinenz.","authors":"Andreas Wiedemann, Barbara Bojack, Claudia Drews, Ruth Kirschner-Hermanns, Klaus Becher","doi":"10.1055/a-2288-2572","DOIUrl":"10.1055/a-2288-2572","url":null,"abstract":"","PeriodicalId":7513,"journal":{"name":"Aktuelle Urologie","volume":"55 6","pages":"549-554"},"PeriodicalIF":0.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Conventional versus high-dose salvage chemotherapy for relapsed testicular germ cell tumours]. [复发睾丸生殖细胞瘤的常规与大剂量挽救性化疗]。
IF 0.3 4区 医学
Aktuelle Urologie Pub Date : 2024-12-01 Epub Date: 2024-08-06 DOI: 10.1055/a-2364-4213
Christoph Oing, Marcus Hentrich
{"title":"[Conventional versus high-dose salvage chemotherapy for relapsed testicular germ cell tumours].","authors":"Christoph Oing, Marcus Hentrich","doi":"10.1055/a-2364-4213","DOIUrl":"10.1055/a-2364-4213","url":null,"abstract":"<p><p>Since the introduction of cisplatin-based combination chemotherapy, patients with metastatic germ cell tumours achieve very high cure rates of >80%. Nevertheless, about 30% of patients relapse despite guideline-endorsed first-line treatment. Of these, again about 50% of patients can still achieve cure with platinum-based salvage chemotherapy and eventually post-chemotherapy residual mass resection.Salvage chemotherapy generally involves platinum-based combination chemotherapy, either as conventional dose cisplatin-based combinations again or as high-dose chemotherapy with subsequent autologous stem cell transplantation.To date, high level evidence from randomised trials supporting the use of salvage high-dose chemotherapy for all patients relapsing after first-line treatment remains lacking, but a large international retrospective registry study had shown a 15% overall survival benefit for patients undergoing salvage high-dose chemotherapy.In this article, we summarise the available literature on the different salvage treatment approaches and discuss these in the light of current treatment guideline recommendations for the management of testicular cancer.</p>","PeriodicalId":7513,"journal":{"name":"Aktuelle Urologie","volume":" ","pages":"543-548"},"PeriodicalIF":0.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141896482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kommentar zu: Skrotumeingriffe: Schmerzkontrolle mit Gabapentin. 疼痛控制：用加巴喷丁控制疼痛。
IF 0.3 4区 医学
Aktuelle Urologie Pub Date : 2024-12-01 Epub Date: 2024-12-03 DOI: 10.1055/a-2349-5765
{"title":"Kommentar zu: Skrotumeingriffe: Schmerzkontrolle mit Gabapentin.","authors":"","doi":"10.1055/a-2349-5765","DOIUrl":"https://doi.org/10.1055/a-2349-5765","url":null,"abstract":"","PeriodicalId":7513,"journal":{"name":"Aktuelle Urologie","volume":"55 6","pages":"490-492"},"PeriodicalIF":0.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kommentar zu: Urothelkarzinom: Urintest CxbT verringert Zystoskopien bei Mikrohämaturien. 尿试验CxbT可减少微血尿的膀胱镜检查。
IF 0.3 4区 医学
Aktuelle Urologie Pub Date : 2024-12-01 Epub Date: 2024-12-03 DOI: 10.1055/a-2343-6313
{"title":"Kommentar zu: Urothelkarzinom: Urintest CxbT verringert Zystoskopien bei Mikrohämaturien.","authors":"","doi":"10.1055/a-2343-6313","DOIUrl":"https://doi.org/10.1055/a-2343-6313","url":null,"abstract":"","PeriodicalId":7513,"journal":{"name":"Aktuelle Urologie","volume":"55 6","pages":"498-500"},"PeriodicalIF":0.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical stage IIA/B seminoma - to do or not to do: the role of retroperitoneal lymphadenectomy]. [临床 IIA/B 期精索瘤--做还是不做：腹膜后淋巴结切除术的作用]。
IF 0.3 4区 医学
Aktuelle Urologie Pub Date : 2024-12-01 Epub Date: 2024-08-01 DOI: 10.1055/a-2358-8224
Axel Heidenreich, Felix Seelemeyer, Ruben Gößmann, Julian Heidenreich, David Pfister
{"title":"[Clinical stage IIA/B seminoma - to do or not to do: the role of retroperitoneal lymphadenectomy].","authors":"Axel Heidenreich, Felix Seelemeyer, Ruben Gößmann, Julian Heidenreich, David Pfister","doi":"10.1055/a-2358-8224","DOIUrl":"10.1055/a-2358-8224","url":null,"abstract":"<p><p>About 10% of patients with seminomatous testicuar germ cell tumors are diagnosed with clinical stage II/B. The current guideline recommended treatment options include systemic chemotherapy with 3 cycles PEB or radiation therapy with 30 Gy for CS IIA and 36 Gy for CS IIB. Despite a high cure rate of 90-94% and 82-90% for CS IIA and CS IIB, respectively, both options are associated with a high rate of treatment-associated long-term toxicities. A significantly increased risk for the development of secondary malignancies, cardiovascular and metabolic disease as well as an increased for treatment-associated mortality has been proven in various studies. Primary nerve sparing retroperitoneal lymph node dissection (nsRPLND) has been evaluated in 5 prospective and retrospective clinical studies and it has emerged as a valid treatment alternative. The relapse-rate after a median follow-up of 25-33 months is in the range of 11-30%, so that 70-90% of patients are cured without being subjected to chemotherapy and potential long-term toxicities. All relapsing patients have been cured with secondary salvage chemotherapy. The frequency of significant surgery-associated complications is low with 3-13%. Therapeutic success depends on the surgical experience of the various surgeons and the chosen template, so that this type of surgical interventions should only be performed in centres of excellence with dedicated surgeons. Preoperative evaluation of the new biomarker miR371 has been shown to predict the presence of metastatic disease with an accuracy of around 100% so that this marker might be used in daily routine prior to active treatment in CS IIA/B seminomas.</p>","PeriodicalId":7513,"journal":{"name":"Aktuelle Urologie","volume":" ","pages":"537-542"},"PeriodicalIF":0.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141873932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[New tumor markers for testicular cancer - in the here and now and in the future]. [睾丸癌的新肿瘤标记物--此时此刻和未来]。
IF 0.3 4区 医学
Aktuelle Urologie Pub Date : 2024-12-01 Epub Date: 2024-10-23 DOI: 10.1055/a-2422-0354
Justine Schoch, Hans Schmelz, Klaus-Peter Dieckmann, Tim Nestler
{"title":"[New tumor markers for testicular cancer - in the here and now and in the future].","authors":"Justine Schoch, Hans Schmelz, Klaus-Peter Dieckmann, Tim Nestler","doi":"10.1055/a-2422-0354","DOIUrl":"10.1055/a-2422-0354","url":null,"abstract":"<p><p>Germ cell tumors of the testis are the most common tumor entities in young men. Since the introduction of platinum-based chemotherapy in the 1970s, most patients can be cured despite the aggressiveness of germ cell tumors. Optimal serum tumor markers are required for diagnostics, therapy monitoring and aftercare, and these are subject to high requirements. The conventional testicular tumor markers human chorionic gonadotropin (hCG), alpha fetoprotein (AFP) and lactate dehydrogenase (LDH) only meet these requirements with insufficient sensitivity (30-70%). The markers investigated in recent decades, such as PLAP, CEA and NSE, have not become established. Currently, miRNA-371 is being researched in particular. Reliable findings are available for initial staging with significantly better specificities of miRNA-371 compared to conventional tumor markers. Further prospective studies are being conducted for other possible clinical applications, such as follow-up care, therapy monitoring or residual tumors, in order to investigate the revolutionary potential of miRNA-371 in these areas as well. Research is also currently being conducted on circulating tumor cells (CTCs) and cell-free DNA (cfNA) in various areas of application. With regard to germ cell tumors of the testis, however, these analyses are still in their infancy, but it is hoped that this will provide a further sufficient opportunity to use serum tumor markers.</p>","PeriodicalId":7513,"journal":{"name":"Aktuelle Urologie","volume":" ","pages":"520-527"},"PeriodicalIF":0.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142492864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信